Bryan Knipe
University of Nebraska Medical Center
9 Papers
Bryan Knipe is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Blood–brain barrier & Occludin. The author has an hindex of 8, co-authored 9 publications. Previous affiliations of Bryan Knipe include Georgia Regents University & Hokkaido University.
Chat about Author
Papers
Alcohol-induced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction
TL;DR: In this paper, the authors investigated the idea that brain microvascular endothelial cells (BMVEC) connected by tight junctions (TJ) form a tight monolayer at the blood-brain barrier (BBB).
285
Alcohol‐induced blood–brain barrier dysfunction is mediated via inositol 1,4,5‐triphosphate receptor (IP3R)‐gated intracellular calcium release
TL;DR: It is suggested that EtOH metabolites act as signaling molecules for the activation of MLCK via the stimulation of IP3R‐gated intracellular Ca2+ release in BMVEC, which can lead to BBB dysfunction in the setting of alcoholism, and to neuro‐inflammatory disorders promoting leukocyte migration across the BBB.
117
Stabilization of superoxide dismutase by acetyl-l-carnitine in human brain endothelium during alcohol exposure: novel protective approach.
TL;DR: The findings suggest the counteracting mechanisms of oxidants and antioxidants during alcohol-induced oxidative stress at the BBB, and the presence of enzymatic stabilizers favors the ROS-neutralizing antioxidant redox of theBBB, suggesting an underlying protective mechanism of NO for brain vascular tone and vasodilation.
53
Peroxisome proliferator-activated receptor-γ activation suppresses HIV-1 replication in an animal model of encephalitis
Raghava Potula,Servio H. Ramirez,Bryan Knipe,Jessica Leibhart,Kathy Schall,David Heilman,Brenda Morsey,Aaron J. Mercer,Anil Papugani,Huanyu Dou,Yuri Persidsky +10 more
TL;DR: In vitro data delineated the novel mechanism by whichPPARγ activation suppresses HIV-1 replication, and in vivo findings underscored the ability of PPARγ agonists to reduce HIV- 1 replication in lymphocytes and brain macrophages, thus offering a new therapeutic intervention in brain and systemic infection.